Eli Lilly Insider Sale: EVP Kenneth Custer Reports Share Disposal and Deferred-Comp Reallocation
Rhea-AI Filing Summary
Kenneth L. Custer, EVP & President, Card Met Hlth at Eli Lilly & Co (LLY), reported insider transactions dated 08/27/2025 and filed 08/28/2025. The filing shows a disposition of 9,346.902 shares of Eli Lilly common stock. It also reports a reallocation within the reporting person's deferred compensation account resulting in 612.937 shares of phantom stock (payable in cash after employment termination). After the reported transactions, the filing states the reporting person beneficially owns 2,173.461 shares of common stock. The form is signed on behalf of Mr. Custer by an authorized representative.
Positive
- Timely disclosure of transactions: transaction dated 08/27/2025 and filing dated 08/28/2025.
- Compliance with Section 16 reporting requirements, including authorized signature on file.
Negative
- Disposition of 9,346.902 shares of Eli Lilly common stock, reducing the reporting person's direct holdings.
- Beneficial ownership reduced to 2,173.461 shares following the reported transactions.
Insights
TL;DR: Routine insider sale and deferred-comp reallocation; disclosure is timely but represents a reduction in direct holdings.
The Form 4 discloses a direct disposition of 9,346.902 shares and an internal reallocation creating 612.937 phantom stock units within a deferred compensation plan. The phantom units are cash-settled upon termination, so they do not increase share count. Reported beneficial ownership after the transactions is 2,173.461 shares. This filing provides transparency on insider liquidity and compensation account changes but contains no additional operational or financial performance information.
TL;DR: Filing meets Section 16 disclosure; transactions appear administrative rather than indicating corporate events.
The report includes an authorized signature and shows the reporting person is both an officer and director. The reallocation noted in the deferred compensation account is explicitly documented as a plan activity, with phantom stock payable in cash. No amendments or irregularities are indicated. From a governance perspective, the form fulfills disclosure obligations without revealing new material corporate governance actions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| I | Phantom Stock | 612.937 | $734.17 | $450K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Each share of phantom stock represents the right to receive the cash value of one share of Eli Lilly and Company common stock. Reflects reallocation of funds within the reporting person's deferred compensation account. Shares of phantom stock are payable in cash following termination of the reporting person's employment with Eli Lilly and Company.
